Increasing trend of diabetes combined with hypertension or hypercholesterolemia: NHANES data analysis 1999-2012.
In order to prevent cardiovascular endpoints, control of diabetes, hypertension and hypercholesterolemia is a necessity as those risk factors frequently occur in combination. Prevalence trends of concurrent diabetes, hypertension and hypercholesterolemia in 36,673 subjects were obtained from the National Health and Nutrition Examination Survey (NHANES) from 1999-2012. The prevalence of concurrent diabetes, hypertension and hypercholesterolemia increased from 3% in 1999-2000 to 6.3% in 2011-2012 (P < 0.001). The diabetes with concurrent hypertension or hypercholesterolemia incidences also increased significantly, while the occurrence of concurrent hypertension and hypercholesterolemia was stable over the study period. Overall medical drug treatments for concurrent diabetes, hypertension, hypercholesterolemia were improved from 69.8% in 1999-2006, to 82.4% in 2007-2012 (P = 0.002). Treatment cost coverage rates in any combinations with diabetes were 79-82.4% and 90.7% in the subgroup of concurrent hypertension and hypercholesterolemia. General treatment goal achievement rates were <25%, the lowest rate being 14.2% in the subject groups with three combined risk factors. The treatment goal achievement rates in two subgroups with concurrent diabetes were 20.1% (with hypertension) and 17% (with hypercholesterolemia) and 24.5% in the group without diabetes. Cost coverage improved in all combinations, but the general treatment goal achievement rates were low, especially in the groups with concurrent diabetes.
Department of Endocrinology and Metabolism, Shandong Provincial Hospital affiliated to Shandong University, No. 324 Jingwu Weiqi Road, Jinan 250021, China.
Yongfeng
Y
Song
Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing 210029, China.
Xiaoyun
X
Liu
MSD China Holding Company, No. 1601 Nanjing West Road, Shanghai 200040, China.
Xiaolin
X
Zhu
MSD China Holding Company, No. 1601 Nanjing West Road, Shanghai 200040, China.
Bin
B
Zhao
Department of Quantitative Health Sciences, Cleveland Clinic. No. 9500 Euclid Avenue Cleveland, Ohio 44195, USA.
Bo
B
Hu
MSD China Holding Company, No. 1601 Nanjing West Road, Shanghai 200040, China.
Xia
X
Sheng
MSD China Holding Company, No. 1601 Nanjing West Road, Shanghai 200040, China.
Lan
L
Chen
Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Diabetes Research Center of Chinese Academy of Medical Sciences &Peking Union Medical College, No. 1 Shuaifu Garden, Beijing 100730, China.
Miao
M
Yu
Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing 210029, China.
Tao
T
Yang
Department of Endocrinology and Metabolism, Shandong Provincial Hospital affiliated to Shandong University, No. 324 Jingwu Weiqi Road, Jinan 250021, China.
Jiajun
J
Zhao
D000368:Aged; D002318:Cardiovascular Diseases / Q000150:complications / Q000453:epidemiology* / Q000473:pathology; D003920:Diabetes Mellitus / Q000453:epidemiology* / Q000473:pathology; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000453:epidemiology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009749:Nutrition Surveys; D009765:Obesity / Q000150:complications / Q000453:epidemiology* / Q000473:pathology; D012307:Risk Factors